Chief Medical Advisor
Dr. Roblin’s career, spanning more than 15 years, has seen him deliver several drugs to the market. He has held leadership roles in Pfizer and Bayer. At Pfizer, Dr. Roblin was most recently Senior Vice President, Head of Research and Site Head for R&D. Dr. Roblin is a Fellow of the Royal College of Physicians and Member of the Faculty of Pharmaceutical Physicians. Dr. Roblin has chaired the Research Director’s Group of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and was a co-founder of the Innovative Medicines Initiative, a $2bn public-private partnership with the European Commission. He is currently an advisor to NOCRI in the NHS.
SmPill® is the main focus of Sigmoid’s current development work and underpins all product development programmes. CyCol®, Sigmoid’s lead clinical development program, which is advancing into Phase 3 trials for moderate to severe ulcerative colitis, was uniquely enabled using SmPill® drug delivery technology.